SECURITIES AND EXCHANGE COMMISSION

                        WASHINGTON, D.C.  20549

                               FORM 8-K

                            CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934



Date  of  Report  (Date  of earliest event reported)       MAY 20, 1996 

                                      ENZON, INC.

                  (Exact name  of  registrant  as  specified  in  its charter)




       DELAWARE                    0-12957              22-237286
   (State or other jurisdiction   (Commission          (IRS Employer
       of incorporation)         File Number)          Identification)



        20 KINGSBRIDGE ROAD,  PISCATAWAY, NEW JERSEY    08854
          (Address of principal executive offices)       (Zip Code)



Registrant's telephone number, including area code    (908) 980-4500




     (Former name or former address, if changed since last report)







ITEM 5.  OTHER EVENTS

          Enzon,  Inc.  ("Enzon"  or the "Company") completed its Phase  Ia
clinical trial in healthy volunteers  at  the  end  of  1995,  and received
approval  from  the  FDA  to  enter  a multi-dose trial in cancer patients.
Enrollment of patients for this trial  has been unexpectedly slow, and as a
result,  the  Company  has  just opened a second  site  and  plans  to  add
additional sites.  The clinical  supplies for the trial have been delivered
to  the  open sites.  To expedite completion  of  this  trial,  a  clinical
research organization  will  be utilized to accelerate patient recruitment,
monitor the study, and compile results.




                            SIGNATURES


     Pursuant to the requirements  of  the Securities Exchange Act of 1934,

the Registrant has duly caused this report  to  be  signed on its behalf by

the undersigned hereunto duly authorized.




Dated:  May 29, 1996




                                              ENZON, INC.
                                             (Registrant)

                                   By:   /s/KENNETH J. ZUERBLIS
                                         Kenneth J. Zuerblis
                                         Vice President, Finance
                                         and Chief Financial
                                         Officer